Drug Trial Radar · NCT05395780
A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer
Last checked: Nov 19, 2026Latest source record: Jun 2, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
30
Planned (sponsor's estimate)
Start
Jun 2022
Primary completion
Dec 2022
Study completion Dec 2023
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Cancer
Interventions
MAX-40279Drug
MAX-40279 capsule will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanjing Drum Tower Hospital of Nanjing University Medical School
Nanjing, Jingsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.